心肌肌球蛋白抑制剂Aficamten的循证进展与未来治疗方向-从机制探索到临床实践
王琦 , 邹云增
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (9) : 1249 -1255.
心肌肌球蛋白抑制剂Aficamten的循证进展与未来治疗方向-从机制探索到临床实践
Evidence-based progress and future therapeutic directions of myosin inhibitor aficamten-from mechanistic exploration to clinical practice
肥厚型心肌病(hypertrophic cardiomyopathy,HCM)是一种常见的遗传性心肌病,其中梗阻型肥厚型心肌病(obstructive hypertrophic cardiomyopathy,oHCM)患者因左心室流出道(left ventricular outflow tract,LVOT)梗阻而面临较高的心力衰竭与心律失常风险。传统药物治疗主要以缓解症状为目标,难以逆转疾病的病理生理进程。心肌肌球蛋白抑制剂(cardiac myosin inhibitors,CMIs)的出现,标志着 HCM 治疗进入了靶向干预疾病核心机制的新时代。Aficamten 凭借其独特的药代动力学特征(如较短半衰期、较低药物相互作用风险)和卓越的疗效与安全性,在多项关键临床试验中证实可显著改善 oHCM 患者的运动耐量、症状和生活质量,并展现出逆转心脏重构的潜力。本文系统综述 Aficamten 的作用机制、药理学特性、临床开发历程及其在 HCM 治疗格局中的定位,并对未来个体化治疗和疾病修饰作用的研究方向进行展望。
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiomyopathy, in which patients with the obstructive form (oHCM) face an elevated risk of heart failure and arrhythmias due to left ventricular outflow tract (LVOT) obstruction. Traditional drug therapies primarily aim to alleviate symptoms and are often unable to reverse the pathophysiological progression of the disease. The advent of cardiac myosin inhibitors (CMIs) marks the entry of HCM treatment into a new era of targeted intervention addressing the core disease mechanism. With its unique pharmacokinetic profile-such as a short half-life and low risk of drug-drug interactions-along with outstanding efficacy and safety, Aficamten has been demonstrated in multiple key clinical trials to significantly improve exercise capacity, symptoms, and quality of life in patients with oHCM, while also showing potential for reversing cardiac remodeling. This article systematically reviews the mechanism of action, pharmacological properties, clinical development history of Aficamten, and its position within the HCM treatment landscape, and offers perspectives on future research directions for personalized therapy and disease-modifying effects.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
唐媛媛, 唐博謇, 严晓伟, |
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
Chuang C, Collibee S, Ashcraft L, |
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
Saberi S, Abraham TP, Choudhury L, |
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
《心肌肌球蛋白抑制剂药物治疗专家共识》工作组, 张志玲. 心肌肌球蛋白抑制剂药物治疗专家共识[J].临床药物治疗杂志, 2026, 24(3): 1-13. |
| [28] |
|
| [29] |
Cytokinetics. Cytokinetics announces NMPA approval of MYQORZO® (aficamten) in China for patients with obstructive hypertrophic cardiomyopathy[EB/OL]. (2025-12-17)[2026-09-17].https://ir.cytokinetics.com/press-releases/press-release-details/2025/Cytokinetics-Announces-NMPA-Approval-of-MYQORZO-aficamten-in-China-for-Patients-with-Obstructive-Hypertrophic-Cardiomyopathy/default.aspx. |
| [30] |
US FDA. Myqorzo (aficamten): NDA approval[EB/OL] (2025-03-09)[2026-09-17].https://www.accessdata.fda.gov/drugsatfda_docs/appleletter/2025/219083Orig1s000ltr.pdf. |
| [31] |
Cytokinetics. Cytokinetics announces European Commission approval of MYQORZO® (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy[EB/OL]. (2026-02-17)[2026-09-17].https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-European-Commission-Approval-of-MYQORZO-aficamten-for-the-Treatment-of-Adults-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy/default.aspx. |
| [32] |
Masri A, Maron MS, Abraham TP, |
| [33] |
|
| [34] |
|
| [35] |
彭娟, 范琳琳, 李然宜, |
| [36] |
|
国家自然科学基金重点项目(82430016)
2026 年度上海市教育科学研究项目(C2026063)
/
| 〈 |
|
〉 |